Halozyme Therapeutics, Inc. (HALO)

66.30 -1.84 (-2.69%) USD  |  NASDAQ  |  Jun 02, 16:00
66.29 -0.02 (-0.02%) After-Hours: 20:00
More

Halozyme Therapeutics Research and Development Expense (% of Annual Revenues)

Research and Development Expense (% of Annual Revenues) Chart

View Research and Development Expense (% of Annual Revenues) for HALO.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Research and Development Expense (% of Annual Revenues) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

R&D Expense Definition

View R&D Expense Definition
Start Trial

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (% of Annual Revenues) Range, Past 5 Years

View Research and Development Expense (% of Annual Revenues) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (% of Annual Revenues) Benchmarks

View Research and Development Expense (% of Annual Revenues) Benchmarks
Start Trial
Vertex Pharmaceuticals, Inc. Upgrade
Agenus, Inc. Upgrade
Altimmune, Inc. Upgrade
Lineage Cell Therapeutics, Inc. Upgrade
Amgen, Inc. Upgrade